# psoriasis - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 47696
- Completion tokens: 16130
- Reasoning tokens: 0
- Total tokens: 63826
- API requests reported: 3
- Elapsed seconds: 131.709
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: OpenAI

---
## Data-quality and evidence status

The ledger contains **100 unique genes**, with **90 upregulated and 10 downregulated**; all 100 have **FDR ≤ 0.01**. The effects are large, including **IL36A log2FC=11.373575**, **DEFB4A log2FC=11.182922**, and **DEFB4B log2FC=11.030811**. This is consistent with a strong lesional-versus-normal skin contrast, but the magnitude and near-uniform statistical significance also warrant checks for tissue composition, batch effects, normalization, and clinical heterogeneity. Sample size, raw expression values, covariate adjustment, and cell-type-resolved data were not supplied.

The direct evidence below is limited to this differential-expression result. **External statistical validation was not performed**: no independent-cohort effect sizes, P values, or FDR values were supplied. GO, Reactome, KEGG, STRING, tissue, disease, and literature records therefore provide biological context rather than replication or proof of mechanism.

## 1. Overall biological interpretation

The profile is strongly compatible with an active psoriatic lesion characterized by coordinated:

1. **IL-36/IL-20-family and IL-17-associated inflammatory signaling**.
2. **Marked epidermal antimicrobial and innate-defense activation**.
3. **Keratinocyte stress, abnormal differentiation, and cornified-envelope remodeling**.
4. **Epidermal hyperplasia and tissue remodeling**.
5. **A possible infiltrating myeloid/neutrophil component**, particularly reflected by **S100A8, S100A12, TCN1, PLBD1, CXCR2**, and related genes.

The most coherent interpretation is not a single isolated cytokine change, but an inflammatory epithelial state in which keratinocytes express cytokine, antimicrobial, junctional, cornification, and stress-response programs while the tissue may also contain increased inflammatory myeloid cells. The downregulated genes—such as **BTC** (log2FC=-4.2989343), **WAKMAR1** (log2FC=-5.6275936), **CYP2W1** (log2FC=-4.7044079), and **UGT3A2** (log2FC=-4.5907749)—are statistically convincing but do not form a clearly interpretable counter-program from the supplied annotations.

## 2. Core biological programs

### Program 1: IL-36/IL-20-family inflammatory epithelial signaling

- **Direction:** Strongly upregulated in lesional skin.
- **Supporting genes:** **IL36A** (log2FC=11.373575, FDR=1.6547601e-98), **IL36G** (5.6840917, 1.4283826e-90), **IL36RN** (3.0051655, 3.8506931e-62), **IL19** (7.5795008, 9.0436597e-84), **IL20** (5.6674194, 2.8540283e-71), **IL26** (4.3612172, 3.7879713e-65), **IRAK2**, **TNIP3**, and **ZC3H12A**.
- **Appropriate pathways:** Reactome **Interleukin-36 pathway** and **Interleukin-20 family signaling**; KEGG **IL-17 signaling pathway** and **cytokine–cytokine receptor interaction**.
- **Interpretation:** Multiple ligands and the endogenous antagonist **IL36RN** are induced together, indicating activation of the IL-36 inflammatory axis with compensatory negative regulation. IL-19, IL-20, and IL-26 provide a related epithelial cytokine signal. The supplied QuickGO and Reactome records support cytokine activity, inflammatory signaling, and JAK–STAT/MAPK-related functions for IL26, while the pathway batch independently identifies IL-17 and cytokine-receptor programs.
- **Evidence strength:** **Strong direct transcriptomic evidence; strong pathway/ontology plausibility; no independent statistical replication.**
- **Limitations:** Increased RNA may reflect both keratinocyte activation and altered cellular composition. The data do not establish which cytokine is upstream, whether the pathway is causal, or whether transcript increases correspond to active extracellular protein.

### Program 2: Antimicrobial and innate epidermal defense

- **Direction:** Strongly upregulated.
- **Supporting genes:** **DEFB4A** (11.182922, FDR=2.1809413e-69), **DEFB4B** (11.030811, 3.6960582e-71), **DEFB103A** (5.7579506, 5.7573064e-68), **DEFB103B** (5.7513848, 1.8566003e-68), **PI3** (9.2403801, 1.5318976e-69), **S100A7** (7.0947825, 3.4915979e-62), **S100A7A** (9.8326673, 9.2520535e-63), **S100A8**, **S100A12**, and **TCN1**.
- **Appropriate pathways:** GO **Antimicrobial humoral response** and **response to lipopolysaccharide**; KEGG **Staphylococcus aureus infection** and **IL-17 signaling**.
- **Interpretation:** The coordinated increase in several β-defensins, PI3, and S100-family genes is characteristic of an activated antimicrobial epithelial environment. This is a program-level signal because it includes multiple defensins and S100 genes rather than one disease-associated marker.
- **Evidence strength:** **Very strong direct evidence; supported by supplied GO/KEGG annotations and disease/tissue literature records.**
- **Limitations:** These genes can respond to barrier disruption, microbial exposure, and inflammatory cytokines. The result does not demonstrate active infection or prove that antimicrobial activity is increased in vivo.

### Program 3: Cornified-envelope formation, keratinocyte stress, and barrier remodeling

- **Direction:** Strongly upregulated.
- **Supporting genes:** **SPRR2A** (7.312080, 2.9333694e-85), **SPRR2B** (6.3799351, 4.0328237e-79), **SPRR2D**, **SPRR2E**, **SPRR2F**, **SPRR2G**, **SPRR3**, **LCE3A** (8.2975962, 1.4167794e-64), **LCE3D**, **KRT6A** (4.3025579, 9.8604235e-68), **GJB2**, **GJB6**, **SERPINB3**, **SERPINB4**, **KLK13**, and **TMPRSS11D**.
- **Appropriate pathways:** Reactome **Formation of the Cornified Envelope**; GO **epidermis development**; epidermal differentiation and cell-junction ontology terms.
- **Interpretation:** The coordinated induction of small proline-rich proteins, late cornified-envelope genes, keratin 6A, desmosome/junction-associated genes, kallikrein-related genes, and serpin genes indicates extensive remodeling of the lesional epidermal barrier. The supplied Reactome module includes **KLK13, KRT6A, LCE3A, LCE3D, and PI3**, and STRING records connect several SPRR and KRT6A genes.
- **Evidence strength:** **Strong direct and pathway evidence; network evidence supports co-membership and associations.**
- **Interaction qualification:** SPRR–SPRR and SPRR–KRT6A relationships in STRING should be interpreted as database-supported network associations or pathway/co-expression relationships unless the specific record demonstrates a physical binding interaction. They are not automatically direct physical interactions.
- **Limitations:** Increased representation of keratinocytes in lesional tissue can amplify this program. The data do not distinguish altered differentiation from increased epidermal thickness or changes in keratinocyte subtype proportions.

### Program 4: Epidermal proliferation and tissue remodeling

- **Direction:** Upregulated.
- **Supporting genes:** **RRM2** (2.7179913, 7.1178258e-62), **CCNE1** (2.5573733, 4.4959113e-61), **KRT6A**, **HPSE** (2.9241399, 3.79011e-78), **WNT5A** (2.5264849, 1.0417283e-67), **FABP5**, **ADGRF1**, **MPZL2**, and **SLC6A14**.
- **Appropriate pathways:** GO **epidermis development** and cell-cycle processes; WNT-related signaling and extracellular-matrix/tissue-remodeling annotations where applicable.
- **Interpretation:** RRM2 and CCNE1 support increased cell-cycle activity, while KRT6A, HPSE, WNT5A, and epithelial metabolic/adhesion genes are consistent with a remodeled, hyperplastic epidermis. This is biologically compatible with the thickened lesional epidermis of psoriasis.
- **Evidence strength:** **Moderate-to-strong direct evidence**, with pathway plausibility; weaker than the cytokine and antimicrobial programs because no formal cell-cycle enrichment statistic was supplied.
- **Limitations:** The result cannot determine whether proliferation is intrinsic to keratinocytes, secondary to cytokine exposure, or partly caused by altered proportions of proliferating cells.

### Program 5: Inflammatory myeloid/neutrophil recruitment or tissue-composition signal

- **Direction:** Upregulated.
- **Supporting genes:** **S100A8** (7.7293672, 6.0481533e-66), **S100A12** (8.3288322, 7.9379823e-97), **TCN1** (8.0353765, 5.4488167e-70), **PLBD1**, **CXCR2** (2.7005582, 9.0755482e-64), **GPR15LG**, **TRIM15**, and **ACP7**.
- **Appropriate pathways:** GO innate immune and inflammatory-response terms; cytokine-receptor and antimicrobial-response pathways.
- **Interpretation:** S100A8/A12 and TCN1 are compatible with infiltrating or activated myeloid/neutrophil populations, while CXCR2 is consistent with chemotactic inflammatory recruitment. This may represent a genuine inflammatory compartment in lesional skin rather than a purely keratinocyte-intrinsic program.
- **Evidence strength:** **Strong direct signal for an inflammatory tissue state; cell-composition interpretation is a supported hypothesis, not a demonstrated cell-fraction estimate.**
- **Limitations:** Bulk tissue data cannot determine whether these transcripts originate from neutrophils, monocytes, keratinocytes, or multiple populations. No single-cell, flow-cytometry, or histologic quantification was provided.

## 3. Key genes and interaction modules

1. **IL36A–IL36G–IL36RN axis**  
   **IL36A** and **IL36G** are strongly upregulated, while the antagonist **IL36RN** is also increased. This supports activation plus feedback regulation of the IL-36 pathway. Their relationship is **pathway co-membership and regulatory antagonism**, not evidence from this dataset of direct protein binding. Reactome records support IL-36 pathway membership.

2. **IL19–IL20–IL26 epithelial cytokine module**  
   All three are strongly upregulated: **IL19** log2FC=7.5795008, **IL20**=5.6674194, and **IL26**=4.3612172. They form an **indirect cytokine-network and pathway relationship**. STRING records for IL26 include associations with IL20RA, IL20RB, IL22RA1, IL10RB, and IL19; these are receptor/interaction annotations, not evidence that all relationships occur in lesional skin.

3. **DEFB4A/DEFB4B–DEFB103A/DEFB103B antimicrobial module**  
   This is among the most extreme signals, with **DEFB4A log2FC=11.182922** and **DEFB4B log2FC=11.030811**. The genes are **co-members of antimicrobial-defense programs** and may be co-regulated by inflammatory signaling. The data do not establish direct physical interactions among defensin proteins.

4. **S100A7/S100A7A–SERPINB3/SERPINB4 epithelial inflammatory module**  
   **S100A7**, **S100A7A**, **SERPINB3**, and **SERPINB4** are all strongly upregulated. STRING records connect S100A7 with several of these genes, but the relationship should be described as **database-supported network association, co-expression, or functional association**, not necessarily direct physical interaction.

5. **SPRR/LCE/KRT6A cornified-envelope module**  
   The SPRR family, **LCE3A/LCE3D**, and **KRT6A** show coordinated induction. STRING records include associations among SPRR genes and KRT6A, and Reactome supports cornified-envelope co-membership. This is primarily a **pathway and structural-module relationship**.

6. **S100A8–S100A12–TCN1 inflammatory myeloid module**  
   These genes are strongly upregulated and collectively suggest an inflammatory myeloid/neutrophil component. The relationship is **cell-type co-occurrence and inflammatory-program co-membership**; the current bulk data do not establish direct interaction or precise cellular origin.

7. **CXCR2-associated recruitment signal**  
   **CXCR2** is upregulated at log2FC=2.7005582, FDR=9.0755482e-64. It may represent a chemotactic recruitment context involving inflammatory cells. This is an **indirect signaling relationship**; ligand abundance, receptor localization, and cell-type origin were not measured.

8. **RRM2–CCNE1 proliferative module**  
   **RRM2** and **CCNE1** are both upregulated and provide convergent evidence of cell-cycle activity. Their relationship is **cell-cycle pathway co-membership**, not a demonstrated direct interaction in this dataset.

9. **CD274 immune-regulatory signal**  
   **CD274** is upregulated (log2FC=3.4395134, FDR=1.8211979e-63), compatible with inducible immune-regulatory signaling in inflamed tissue. This is an **expression association**; it does not establish functional immune suppression or therapeutic relevance in psoriasis.

## 4. Validation priorities

### 1. Keratinocyte IL-36/IL-20 inflammatory circuit  
- **Classification:** Mechanistic hypothesis.
- **Why prioritize:** It is supported by multiple highly significant cytokine transcripts, including IL36A, IL36G, IL19, IL20, and IL26, together with IL36RN feedback.
- **Current evidence:** Direct lesional-skin differential expression plus Reactome/QuickGO support for IL-36, IL-20-family, cytokine, and JAK–STAT-related biology.
- **External evidence:** Published psoriasis literature and the supplied psoriasis biomarker record (**PMID: 40560938**) provide contextual support, but no independent cohort statistic was supplied.
- **Next step:** Measure cytokine protein and pathway activation in lesional keratinocytes using spatial transcriptomics, immunostaining, multiplex cytokine assays, or lesional keratinocyte cultures; perturb IL36A/IL36G or their receptors.
- **Conclusion level:** **Supported hypothesis**, not established causality.

### 2. Defensin/S100 antimicrobial signature as a lesion biomarker  
- **Classification:** Biomarker.
- **Why prioritize:** Multiple antimicrobial genes show large, concordant effects, especially DEFB4A, DEFB4B, DEFB103A/B, PI3, S100A7, and S100A7A.
- **Current evidence:** Very strong differential-expression signal and supplied antimicrobial-humoral-response, LPS-response, and infection-related pathway annotations.
- **External evidence:** Tissue and disease annotations support biological plausibility; literature records involving defensin-associated genes are not equivalent to validation in this psoriasis cohort.
- **Next step:** Test the signature in an independent psoriasis cohort, compare lesional, nonlesional, and normal skin, and relate expression to PASI, treatment response, and microbial measures.
- **Conclusion level:** **Supported hypothesis** as a tissue-state marker; clinical utility is **insufficient evidence**.

### 3. Myeloid/neutrophil composition versus keratinocyte-intrinsic inflammation  
- **Classification:** Confounding or composition check.
- **Why prioritize:** S100A8, S100A12, TCN1, PLBD1, and CXCR2 may reflect infiltrating inflammatory cells and could substantially influence bulk-tissue results.
- **Current evidence:** Strong coordinated upregulation, but no cell-type proportions were supplied.
- **External evidence:** Gene/tissue annotations support myeloid and inflammatory interpretations, but database records do not quantify the cellular contribution in these samples.
- **Next step:** Perform single-cell or spatial RNA sequencing, immunohistochemistry for neutrophil/monocyte markers, and cell deconvolution using validated reference profiles.
- **Conclusion level:** **Supported hypothesis**, with the composition component currently **insufficiently resolved**.

### 4. SPRR/LCE/KRT6A barrier-remodeling network  
- **Classification:** Interaction/network hypothesis.
- **Why prioritize:** Multiple structural and cornified-envelope genes are concordantly induced, and the supplied Reactome and STRING records support network-level organization.
- **Current evidence:** Strong direct expression and pathway co-membership; STRING provides functional/network associations.
- **External evidence:** Cornified-envelope and epidermal-development annotations support plausibility, but they do not prove direct physical interactions or causal hierarchy.
- **Next step:** Use spatial or single-cell profiling and keratinocyte perturbation experiments to test whether inflammatory cytokine blockade reverses the SPRR/LCE/KRT6A program.
- **Conclusion level:** **Supported hypothesis** for a coordinated barrier-remodeling program; direct interaction claims remain **exploratory**.

### 5. IL-36-axis therapeutic relevance  
- **Classification:** Therapeutic target.
- **Why prioritize:** IL36A and IL36G are among the strongest signals, and the axis is biologically coherent with the inflammatory epithelial phenotype.
- **Current evidence:** Strong lesional expression and pathway annotation.
- **External evidence:** Literature and pathway records support plausibility, but the supplied evidence contains no psoriasis treatment-response analysis, randomized intervention result, or independent therapeutic statistic. Drug or clinical-trial record presence alone is not evidence of efficacy.
- **Next step:** Test pathway inhibition in patient-derived keratinocyte/skin organoid systems and assess effects on cytokine, defensin, and cornified-envelope outputs; then evaluate clinical response in appropriately designed trials.
- **Conclusion level:** **Exploratory-to-supported therapeutic hypothesis**, not an established effective target.

## 5. Major limitations and alternative explanations

1. **Tissue and cell-composition differences:**  
   Lesional skin contains altered proportions of keratinocytes, immune cells, and vascular/stromal components. This could explain part of the S100A8/S100A12/TCN1 signal and may amplify epithelial markers. Single-cell, spatial profiling, histology, and deconvolution should be used to distinguish composition from within-cell regulation.

2. **Disease severity and treatment exposure:**  
   Lesion activity, chronicity, recent topical or systemic therapy, and sampling site can strongly affect inflammatory and barrier genes. Clinical metadata and stratified analyses are needed.

3. **Batch, platform, and normalization effects:**  
   The extreme effect sizes and universal FDR significance should be checked against sample-level distributions, principal components, library quality, batch variables, and negative-control genes. Technical artifacts cannot be excluded from the supplied summary table.

4. **Broad pathway overlap:**  
   IL-17, cytokine, antimicrobial, epidermal-development, and infection-related annotations share many genes and may derive from overlapping annotation sources. Their recurrence is biological plausibility, not a newly computed enrichment P value or independent replication.

5. **Association does not establish causation:**  
   The data identify a lesional expression state. They do not determine whether cytokine activation causes epidermal remodeling, whether barrier disruption initiates inflammation, or whether both are consequences of another upstream process.

Overall, the most defensible interpretation is a highly inflamed, antimicrobial, hyperplastic, and barrier-remodeled psoriatic epidermis with a probable inflammatory myeloid contribution; the IL-36/IL-20-family axis and the defensin–cornified-envelope programs are the highest-priority hypotheses for spatial, protein-level, mechanistic, and independent-cohort validation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=17, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
